Table of Contents

TABLE OF CONTENTS
CHAPTER 1 ABOUT THIS PROFILE 2
Executive summary 2
Quarterly news update 2
Company introduction 2
Company sales 2
Company financials 2
Key products and competitors 3
Data sourcing 3
Sales data 3
Analyst consensus 3
CHAPTER 2 EXECUTIVE SUMMARY 4
Key findings 4
Prescription pharmaceutical sales performance, 2001–13 5
Financial performance, 2001–13 6
Genentech: PharmaVitae forecasts at a glance 8
Strategic insight 9
Genentech, the leading therapeutic monoclonal antibody player 9
Genentech’s relationship with Roche a key factor to success 10
Genentech’s ‘Big Three’ 11
Successful ‘land grab’ locks out competition 12
Horizontal expansion of key products 13
Genentech’s core growth 13
A plethora of future approvals for Avastin the key driver 15
Genentech: Avastin-centered growth strategy 16
SWOT analysis 18
Strengths 18
Weaknesses 19
Opportunities 19
Threats 19
CHAPTER 3 QUARTERLY NEWS UPDATE 30
Product developments 30
Deals and alliances 31
Product deals 31
Technology deals 32
M&A activity 32
Company announcements 33
Future product milestones 34
CHAPTER 4 COMPANY INTRODUCTION 35
Key findings 35
Background 36
Key corporate developments 37
Founding 37
Genentech’s first product 37
Genentech’s first mAb therapy 38
M&A history 40
Genentech’s history with its partner Roche 40
Genentech’s agreement with Roche 41
…But Roche makes Genentech acquisition bid 42
Genentech makes first acquisition: Tanox 43
Current corporate structure 45
CHAPTER 5 COMPANY SALES 46
Key findings 46
Prescription pharmaceutical sales and growth rate analysis, 2001–13 47
Product analysis 50
Product analysis, 2001–07 50
Product analysis, 2007–13 54
Therapy area analysis 58
Therapy area analysis, 2001–07 59
Therapy area analysis, 2001–07 59
Therapy area analysis, 2007–13 61
Therapy area focus, 2001–13 64
Geographic analysis 65
Geographic analysis, 2001–07 66
Geographic analysis, 2001–07 66
Geographic analysis, 2007–13 67
Geographic focus, 2001–13 68
Launch/core/expiry analysis 69
Explanation of launch/core/expiry analysis 69
Launch analysis, 2007–13 70
Core analysis, 2007–13 71
Expiry analysis, 2007–13 73
Launch/core/expiry configuration, 2007–13 74
Molecule type analysis 76
Molecule type analysis, 2001–07 77
Molecule type analysis, 2007–13 79
Externalization analysis 81
Externalization analysis, 2001–07 82
Externalization analysis, 2007–13 84
CHAPTER 6 COMPANY FINANCIALS 86
Key findings 86
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001–07 87
Financial statements, 2001–07 90
Profit and loss account, 2001–07 90
Balance sheet, 2001–07 93
Operating costs and profit analysis 95
Operating costs and profit analysis, 2001–07 97
Operating cost ratio and profit margin analysis, 2001–07 98
Operating cost ratio and profit margin analysis, 2007–13 100
Operating costs and profit analysis, 2007–13 102
CHAPTER 7 KEY PRODUCTS AND COMPETITORS 104
Key findings 104
Overview 105
Oncology 106
Avastin 106
Rituxan 110
Herceptin 113
Tarceva 116
Immunology & inflammation 119
Ocrelizumab 119
Rituxan RA 122
Other 125
Lucentis 125
CHAPTER 8 APPENDIX 128
R&D pipeline 128
References 131
Abbreviations 131


TABLE OF TABLES
Table 1: Genentech – PharmaVitae forecasts at a glance 8
Table 2: Genentech key product developments, 2008 30
Table 3: Genentech product deals and alliances, 2008 31
Table 4: Genentech technology deals and alliances, Q1 2008 32
Table 5: Genentech M&A activity, 2008 32
Table 6: Genentech company announcements, 2008 33
Table 7: Genentech future product milestones, 2008–10 34
Table 8: Genentech product portfolio overview ($m), 2001–07 50
Table 9: Genentech product portfolio overview ($m), 2007–13 54
Table 10: Genentech portfolio by therapy area ($m), 2001–07 59
Table 11: Genentech portfolio by therapy area ($m), 2007–13 61
Table 12: Genentech portfolio overview by geographic region ($m), 2001–07 66
Table 13: Genentech portfolio overview by geographic region ($m), 2007–13 67
Table 14: Genentech launch portfolio overview ($m), 2007–13 70
Table 15: Genentech core portfolio overview ($m), 2007–13 71
Table 16: Genentech expiry portfolio overview ($m), 2007–13 73
Table 17: Genentech portfolio overview by molecule type ($m), 2001–07 77
Table 18: Genentech product portfolio overview by molecule type ($m), 2007–13 79
Table 19: Genentech product portfolio overview by source ($m), 2001–07 82
Table 20: Genentech product portfolio overview by source ($m), 2007–13 84
Table 21: Total Genentech sales by business unit ($m), 2001–07 87
Table 22: Genentech profit and loss account ($m), 2001–07 90
Table 23: Genentech balance sheet ($m), 2001–07 93
Table 24: Genentech operating revenue/cost analysis ($m), 2001–07 97
Table 25: Genentech operating cost ratio analysis (% of total revenues), 2001–07 98
Table 26: Genentech operating cost ratio analysis (% of total revenues), 2007–13 100
Table 27: Genentech operating revenue/cost analysis ($m), 2007–13 102
Table 28: Key products overview 105
Table 29: Avastin: overview 106
Table 30: Avastin: sales forecast ($m), 2007–13 107
Table 31: Rituxan: overview 110
Table 32: Rituxan: sales forecast ($m), 2007–13 111
Table 33: Herceptin: overview 113
Table 34: Herceptin: sales forecast ($m), 2007–13 114
Table 35: Tarceva: overview 116
Table 36: Tarceva: sales forecast ($m), 2007–13 117
Table 37: ocrelizumab: overview 119
Table 38: ocrelizumab: sales forecast ($m), 2007–13 120
Table 39: Rituxan RA: overview 122
Table 40: Rituxan RA: sales forecast ($m), 2007–13 123
Table 41: Lucentis: overview 125
Table 42: Lucentis: sales forecast ($m), 2007–13 126
Table 43: Genentech’s R&D pipeline (Phase I–registration) 128
Table 44: Genentech’s indication broadening pipeline (Phase I–registration) 129


TABLE OF FIGURES
Figure 1: Genentech prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001–13 5
Figure 2: Genentech’s financial performance ($m), 2001–13 7
Figure 3: Genentech launch/core/expiry configuration ($m), 2007–13 14
Figure 4: Avastin’s potential approvals within the forecast period 15
Figure 5: Genentech’s reliance on Avastin 17
Figure 6: Genentech SWOT analysis 18
Figure 7: Corporate structure 45
Figure 8: Genentech prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001–13 48
Figure 9: Genentech key sales growth driver & resistors ($m), 2001–07 51
Figure 10: Genentech key sales growth drivers & resistors ($m), 2007–13 55
Figure 11: Genentech prescription pharmaceutical sales by therapy area ($m), 2001–13 58
Figure 12: Genentech prescription pharma sales by therapy area (% of total), 2001–13 64
Figure 13: Genentech prescription pharmaceutical sales by geographic region ($m), 2001–13 65
Figure 14: Genentech growth drivers and resistors by geographic region ($m), 2001–07 66
Figure 15: Genentech drivers and resistors by geographic region ($m), 2007–13 67
Figure 16: Genentech prescription pharmaceutical sales by geographic region (% of total), 2001–13 68
Figure 17: Genentech launch/core/expiry configuration ($m), 2007–13 74
Figure 18: Genentech prescription pharmaceutical sales by molecule type ($m), 2001–13 76
Figure 19: Genentech growth drivers and resistors by molecule type ($m), 2007–13 79
Figure 20: Genentech prescription pharmaceutical sales by source ($m), 2001–13 81
Figure 21: Genentech growth drivers and resistors by source ($m), 2001–07 82
Figure 22: Genentech growth drivers and resistors by source ($m), 2007–13 84
Figure 23: Genentech operating revenue/cost analysis ($m), 2001–13 96
Figure 24: Genentech operating cost ratio analysis (% of total revenues), 2001–13 101